From November 1, 2023 to March 15, 2024, the company has repurchased 235,168 shares, representing 2.7% for $0.41 million. With this, the company has completed the repurchase of 2,196,623 shares, representing 13.94% for $6.21 million under the buyback announced on February 2, 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.08 USD | +3.48% |
|
-0.48% | -3.70% |
17/06 | MyMD Pharmaceuticals, Inc. announced that it has received $14 million in funding from PharmaCyte Biotech, Inc. | CI |
23/05 | MyMD Pharmaceuticals, Inc. amended terms of the transaction | CI |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.70% | 1.7Cr | |
+55.95% | 81TCr | |
+43.62% | 64TCr | |
-6.98% | 35TCr | |
+19.08% | 33TCr | |
+9.05% | 30TCr | |
+16.30% | 25TCr | |
+2.41% | 22TCr | |
+12.47% | 22TCr | |
+8.91% | 17TCr |
- Stock Market
- Equities
- PMCB Stock
- News PharmaCyte Biotech, Inc.
- Tranche Update on PharmaCyte Biotech, Inc.'s Equity Buyback Plan announced on February 2, 2023.